Low molecular weight heparins in the treatment of lung cancer

Expert Opinion on Investigational Drugs

Volumn 20, Issue 11, 2011, Pages 1517-1522

  Mellema, Wouter W ^a   Smit, Egbert F ^a   Dingemans, Anne Marie C ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Low molecular weight heparin; Lung cancer; Thromboembolic events

Indexed keywords

ANTIVITAMIN K; CISPLATIN; DALTEPARIN; DOCETAXEL; ENOXAPARIN; GEMCITABINE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PEMETREXED; TINZAPARIN;

ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER PATIENT; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY (TOPIC); NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG EVALUATION, PRECLINICAL; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LUNG NEOPLASMS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 80054009298     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.625008     Document Type: Review

References (42)

1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26(21):3552-9
2. Trousseau A. Phlegmasia alba dolens. Clin Med Hotel Dieu de Paris 1865;3:659-712
3. Hettiarachchi RJ, Lok J, Prins MH, Buller HR. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer 1998;83(1):180-5 (Pubitemid 28299645)
4. Saba HI, Khalil FK, Morelli GA, et al. Thromboembolism preceding cancer: a correlation study. Am J Hematol 2003;72(2):109-14 (Pubitemid 36164345)
5. van der Heiden PL, Prins MH, de Monye W, et al. Pulmonary embolism as a first clinical sign of occult malignancy: a prospective follow-up study. Thromb Haemost 2006;95(3):584-5
6. El Sakka K, Gambhir RP, Halawa M, et al. Association of malignant disease with critical leg ischaemia. Br J Surg 2005;92(12):1498-501 (Pubitemid 41785288)
7. Blom JW, Vanderschoot JP, Oostindier MJ, et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006;4(3):529-35
8. Tagalakis V, Levi D, Agulnik JS, et al. High risk of deep vein thrombosis in patients with non-small cell lung cancer: a cohort study of 493 patients. J Thorac Oncol 2007;2(8):729-34 (Pubitemid 47357525)
9. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293(6):715-22 (Pubitemid 40216041)
10. Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343(25):1846-50 (Pubitemid 32104130)
11. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78(5):285-91 (Pubitemid 29439263)
12. Numico G, Garrone O, Dongiovanni V, Silvestris N. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005;103(5):994-9 (Pubitemid 40270076)
13. Louzada ML, Majeed H, Dao V, et al. Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies. Blood Coagul Fibrinolysis 2011;22(2):86-91
14. Gale AJ, Gordon SG. Update on tumor cell procoagulant factors. Acta Haematol 2001;106(1-2):25-32 (Pubitemid 32830513)
15. Varon D, Brill A. Platelets cross-talk with tumor cells. Haemostasis 2001;31(Suppl 1):64-6
16. Marinho FC, Takagaki TY. Hypercoagulability and lung cancer. J Bras Pneumol 2008;34(5):312-22
17. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000;85(9):967-72
18. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349(2):146-53. (Pubitemid 36818784)
19. Meyer G, Marjanovic Z, Valcke J, et al.Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162(15):1729-35.
20. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25(34):5490-505 (Pubitemid 350232226)
21. Akl EA, Barba M, Rohilla S, et al. Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review. J Exp Clin Cancer Res 2008;27:21
22. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10(10):943-9
23. Albert-Weil J, Nehorias J. Two cases of neoplasms not justified for classical therapy, treated with intravenous injections of heparin and intramuscular injections of leech extracts. Rev Pathol Gen Physiol Clin 1954;54(660):1014-20
24. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100(10):3484-8 (Pubitemid 35303914)
25. von Delius S, Ayvaz M, Wagenpfeil S, et al. Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb Haemost 2007;98(2):434-9 (Pubitemid 47250248)
26. Icli F, Akbulut H, Utkan G, et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol 2007;95(6):507-12 (Pubitemid 46709395)
27. Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160(2):181-8 (Pubitemid 30054337)
28. Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 1994;74(1):38-45 (Pubitemid 24187607)
29. Vlodavsky I, Ilan N, Nadir Y, et al. Heparanase, heparin and the coagulation system in cancer progression. Thromb Res 2007;120(Suppl 2):S112-20 (Pubitemid 350101779)
30. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001;108(3):341-7 (Pubitemid 32730777)
31. Borsig L, Wong R, Feramisco J, et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001;98(6):3352-7 (Pubitemid 32220849)
32. Castelli R, Porro F, Tarsia P. The heparins and cancer: review of clinical trials and biological properties. Vasc Med 2004;9(3):205-13 (Pubitemid 40124086)
33. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998;80(1):10-23 (Pubitemid 28353491)
34. Gerotziafas GT, Papageorgiou C, Hatmi M, et al. Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb 2008;36(3-4):204-11
35. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23(10):2123-9. (Pubitemid 46218703)
36. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22(10):1944-8. (Pubitemid 41095187)
37. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23(10):2130-5. (Pubitemid 46218704)
38. Sideras K, Schaefer PL, Okuno SH, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006;81(6):758-67. (Pubitemid 43839491)
39. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2(8):1266-71. (Pubitemid 40186120)
40. van Doormaal FF, Di Nisio M, Otten HM, et al. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011;29(15):2071-6.
41. Dingemans AC, Smit EF, van der Heijden E, et al. A randomised phase III study of adjuvant chemotherapy in PET-selected patients with completely resected non-small cell lungs cancer (NSCLC): NVALT 8. Ann Oncol 2008;19:Suppl 8, pg viii97
42. Griffiths GO, Burns S, Noble SI, et al. FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer 2009;9:355